Dendritic cell populations during HIV primary infection
| Patient . | CD123+ DC/mL blood (% vs PBMCs) . | CD11c+ DC/mL blood (% vs PBMCs) . | ||||||
|---|---|---|---|---|---|---|---|---|
| before HAART . | after HAART . | before HAART . | after HAART . | |||||
| 1 | 5 270 | 0.25 | 6 060 | 0.29 | 7 370 | 0.35 | 2 920 | 0.14 |
| 2 | 4 150 | 0.13 | 4 000 | 0.13 | 7 020 | 0.22 | 1 540 | 0.05 |
| 3 | 7 550 | 0.19 | 4 560 | 0.16 | 5 960 | 0.15 | 2 850 | 0.10 |
| 4 | 1 470 | 0.06 | 1 090 | 0.05 | 5 860 | 0.24 | 870 | 0.04 |
| 5 | 8 950 | 0.20 | 1 630 | 0.12 | 13 000 | 0.29 | 2 720 | 0.20 |
| 6 | 5 320 | 0.18 | 1 520 | 0.06 | 4 140 | 0.14 | 760 | 0.03 |
| 7 | 4 200 | 0.19 | 990 | 0.04 | 6 400 | 0.29 | 3 230 | 0.13 |
| 8 | 1 980 | 0.08 | 2 790 | 0.07 | 4 000 | 0.18 | 15 080 | 0.27 |
| 9 | 2 300 | 0.13 | 13 700 | 0.29 | 4 600 | 0.26 | 12 000 | 0.33 |
| 10 | 5 500 | 0.27 | 3 100 | 0.13 | 4 900 | 0.51 | 10 400 | 0.22 |
| 11 | 6 240 | 0.24 | 11 200 | 0.32 | 1 300 | 0.05 | 5 950 | 0.17 |
| 12 | 150 | 0.01 | 5 730 | 0.39 | 760 | 0.05 | 7 350 | 0.50 |
| 13 | 3 080 | 0.08 | 1 410 | 0.03 | 7 310 | 0.19 | 6 580 | 0.14 |
| Mean ± SD | 4 320 ± 2 510 | 0.15 ± 0.08 | 4 450 ± 3 970 | 0.16 ± 0.12 | 5 590 ± 3 050 | 0.22 ± 0.12 | 5 560 ± 4 550 | 0.18 ± 0.13 |
| P vs controls | P = .0002 | P < .0001 | P = .0009 | P = .0009 | P = .001 | P = .003 | P = .003 | P = .0007 |
| HIV− controls (n = 13) | 12 300 ± 6500 | 0.43 ± 0.19 | 16 900 ± 14 300 | 0.60 ± 0.46 | ||||
| Patient . | CD123+ DC/mL blood (% vs PBMCs) . | CD11c+ DC/mL blood (% vs PBMCs) . | ||||||
|---|---|---|---|---|---|---|---|---|
| before HAART . | after HAART . | before HAART . | after HAART . | |||||
| 1 | 5 270 | 0.25 | 6 060 | 0.29 | 7 370 | 0.35 | 2 920 | 0.14 |
| 2 | 4 150 | 0.13 | 4 000 | 0.13 | 7 020 | 0.22 | 1 540 | 0.05 |
| 3 | 7 550 | 0.19 | 4 560 | 0.16 | 5 960 | 0.15 | 2 850 | 0.10 |
| 4 | 1 470 | 0.06 | 1 090 | 0.05 | 5 860 | 0.24 | 870 | 0.04 |
| 5 | 8 950 | 0.20 | 1 630 | 0.12 | 13 000 | 0.29 | 2 720 | 0.20 |
| 6 | 5 320 | 0.18 | 1 520 | 0.06 | 4 140 | 0.14 | 760 | 0.03 |
| 7 | 4 200 | 0.19 | 990 | 0.04 | 6 400 | 0.29 | 3 230 | 0.13 |
| 8 | 1 980 | 0.08 | 2 790 | 0.07 | 4 000 | 0.18 | 15 080 | 0.27 |
| 9 | 2 300 | 0.13 | 13 700 | 0.29 | 4 600 | 0.26 | 12 000 | 0.33 |
| 10 | 5 500 | 0.27 | 3 100 | 0.13 | 4 900 | 0.51 | 10 400 | 0.22 |
| 11 | 6 240 | 0.24 | 11 200 | 0.32 | 1 300 | 0.05 | 5 950 | 0.17 |
| 12 | 150 | 0.01 | 5 730 | 0.39 | 760 | 0.05 | 7 350 | 0.50 |
| 13 | 3 080 | 0.08 | 1 410 | 0.03 | 7 310 | 0.19 | 6 580 | 0.14 |
| Mean ± SD | 4 320 ± 2 510 | 0.15 ± 0.08 | 4 450 ± 3 970 | 0.16 ± 0.12 | 5 590 ± 3 050 | 0.22 ± 0.12 | 5 560 ± 4 550 | 0.18 ± 0.13 |
| P vs controls | P = .0002 | P < .0001 | P = .0009 | P = .0009 | P = .001 | P = .003 | P = .003 | P = .0007 |
| HIV− controls (n = 13) | 12 300 ± 6500 | 0.43 ± 0.19 | 16 900 ± 14 300 | 0.60 ± 0.46 | ||||
PBMCs indicates peripheral blood mononuclear cells; HAART, highly active antiretroviral therapy.